Search This Blog

Sunday, October 6, 2024

As I sit here on day 10 of hurricane-ravaged western North Carolina with no power or water ...

 By M. Walter

As I sit here on day ten of no power/water in Hurricane Helene-ravaged Western North Carolina, it occurs to me: why did none of the trillions we’ve spent on “infrastructure” do something eminently sensible, like bury all the wires?

“Burying wires costs a fortune,” you say.

Well, if a trillion bucks ain’t a fortune, I’d sure like to know what is. 

The streets should’ve been paved in gold for that money, ferheavensakes.

In the last week here, I heard one “expert” (beware those experts) say that if a power line’s pole goes down and has to be completely replaced, it takes three to four hours for the linemen to replace it and make it ready to go. 

Multiply that by how many times and in how many locations, per year, year after year, that exact thing needs doing, and pretty soon you’re talking about real money.

Not a trillion, but real money. Not to speak of the ridiculous, repetitive tediousness of it all. 

Enough already. 

If we’re going to spend ourselves into un-pay-back-able debt, then let’s at least go with the damned lights on.

I saw something else storm-related today that caught my eye: 

FEMA’s Spokesperson and Director of Public Affairs, Jaclyn Rothenberg, locked down her personal X/Twitter account. 

Now, I distinctly remember lefties making a literal federal case out of another high official limiting access to his personal account: one Donald J. Trump.

When then-President Trump blocked some individual propagandists, there was a great hue and cry from the left. They went to court saying his personal account should be deemed official.  “We’ve got to be able to see what the Leader of the Free World is tweeting,” they said.  “We have rights!”

Of course, nobody was violating any “rights.”  All they had to do was sign out of Twitter then go to www.twitter.com/realDonaldTrump and voilĂ , there were his tweets.  All of ‘em.  In all their MAGA glory. 

Ultimately the Supreme Court got involved, by which time President Trump was no longer in office so on those grounds, they dismissed it as moot.

The irony of it all was that the left brought the case based on viewpoint discrimination in the public square.

Yeah, we know something about viewpoint discrimination on Twitter.  We know what that looks like.  Know it when we see it.  Well, when you lock down your tweets, as the FEMA spox has done, it really is viewpoint discrimination because unless you agree with her, she won’t let you see her tweets, logged in or out.  They’re blocked.

Don’t hold your breath for anyone to make a literal federal case about this. You might be waiting at least as long as I have just to get my lights turned on.

https://www.americanthinker.com/blog/2024/10/as_i_sit_here_on_day_10_of_hurricane_ravaged_western_north_carolina_with_no_power_or_water.html

Regeneron co-founder warns of harms from weight-loss drugs

 The co-founder of biotech firm Regeneron Pharmaceuticals (NASDAQ:REGN) said in a newspaper interview that popular weight-loss drugs could be harmful to people who lose too much muscle mass that’s seen as helpful in keeping the weight off. His company is currently testing medicines to preserve muscle mass.

The weight-loss drugs known as GLP-1s have been shown in clinical studies to cause muscle loss that exceeds what people lose when they try shedding pounds through diet or exercise.

This muscle loss adds “insult to injury” for patients who discontinue GLP-1s and gain back weight, George Yancopoulos, who also is Regeneron’s (REGN) chief scientific officer, higher body fat percentage that’s associated with other health problems, he said.

Drug Trials

Regeneron (REGN) isn’t alone in researching experimental treatments for preserving lean muscle mass when combined with GLP-1 drugs that curb appetite. If the $130 billion market for GLP-1 drugs is any indication, there is ample demand for muscle-preserving treatments.

Novo Nordisk (NVO) (OTCPK:NONOF) currently markets Ozempic and Wegovy for weight loss, while Eli Lilly (NYSE:LLY) makes Mounjaro and Zepbound.

Regeneron (REGN) is testing a drug called trevogrumab that blocks the hormone myostatin, preventing from limiting muscle growth, in combination with Wegovy in mid-stage trials.

Meanwhile, there are 11 myostatin drugs in the industry pipeline, of which seven are being investigated for obesity, the FTI reported, citing data from industry tracker Citeline.

Eli Lilly (LLY) last year acquired Versanis for $1.9 billion to obtain a muscle-preserving treatment. Newly listed BioAge Labs (NASDAQ:BIOA) partnered with Eli Lilly (LLY) on a treatment to prevent muscle loss.

https://www.msn.com/en-us/money/companies/regeneron-co-founder-warns-of-harms-from-weight-loss-drugs-ft/ar-AA1rMGcp

Taxpayer-Funded Minneapolis Food Pantry Comes Under Fire For Discrimination

 A food pantry in Minneapolis has come under fire for explicitly barring white people from accessing its services.

According to the Daily Mail, Mykela "Keiko" Jackson, the director of the Food Trap Project Bodega, which was set up with a Minnesota State grant and located near the Sanctuary Covenant Church in North Minneapolis, quickly became the subject of intense scrutiny and criticism when it posted a sign stating that the food was intended exclusively for "Black and Indigenous Folx."

Jackson's racist policy led to a civil rights complaint after it denied service to several white individuals, including local chaplain Howard Dotson, who filed the complaint with the Minneapolis Civil Rights Commission. He described his experience as deeply divisive, telling Alpha News, "This is not building community, it's destroying it," adding "I went over there and confronted her. I told her that I saw the sign and I asked if she really thought she could take grant money from the state and discriminate against poor white people." Dotson's frustration was echoed by many in the community who saw the pantry's policy as a step backward in race relations and community cohesion.
Dotson, seen here with the Governor of Minnesota Tim Walz, filed a complaint with the Minneapolis Civil Rights Commission

Jackson defended the policy, stating that the pantry was established to serve black and indigenous communities affected by systemic inequalities and that white individuals could find resources elsewhere. Her stance sparked further debate about the role of racial criteria in public service and whether such measures heal or deepen societal divisions.

The backlash grew so intense that the pantry was forced to relocate after the church stated the project's approach had strayed from the inclusive vision initially proposed.

Jackson, however, claims that the pantry hasn't turned anyone away.

"There was no one there directly turning them away. They felt entitled to the resources that were not for their demographic - white privilege is real," she said, accusing Dotson of 'political violence.'

Jackson said on Instagram that the pantry was forced to move because of a "karen."

"It has been recently brought to our attention that our partnership with Sanctuary Church may not be fully aligned with our mission due to a recent incident with a "Karen" last week," she wrote. "Although the church likes our concept they feel our commitment towards directing these resources towards Black & Indigenous families ONLY is exclusionary to other POC & White members of the community that use their establishment."

According to Jackson's website, "The Black community consistently faces hunger at higher rates than whites due to racism within social, economic and environmental aspects."

Sanctuary Covenant Church, meanwhile, said Jackson misled them.

"When Mykela Jackson approached us to set up her Food Trap Project we were excited to support her. This would be a place accessible to anyone 24./7. No demographic [information] necessary. Anyone in need would be welcome. 

"Nowhere in her original proposal did she indicate that she would be restricting usage to specific communities. This does not align with the vision and mission of the Sanctuary.

"When we discovered her signage and social media posts, we asked her to abide by her original proposal. Ms. Jackson was unable to do so and decided to move her Food Trap elsewhere. The deadline for moving her trap is 9/30. We've already cut power to it."

https://www.zerohedge.com/political/black-indigenous-folx-only-taxpayer-funded-minneapolis-food-pantry-comes-under-fire

Activist investor Starboard Value takes $1 billion stake in Pfizer

 Activist investor Starboard Value has taken a roughly $1 billion stake in Pfizer and wants the U.S. drug giant to make changes to turn its performance around, the Wall Street Journal reported on Sunday.

https://finance.yahoo.com/news/activist-investor-starboard-value-takes-001331523.html

SPAC Oaktree Acquisition III Life Sciences files for a $175 million IPO

 Oaktree Acquisition III Life Sciences, a blank check company formed by Oaktree Capital targeting healthcare businesses, filed on Friday with the SEC to raise up to $175 million in an initial public offering.


The Los Angeles, CA-based company plans to raise $175 million by offering 17.5 million units at $10 per unit. Each unit consists of one share of common stock and one-fifth of a warrant, exercisable at $11.50. At the proposed deal size, Oaktree Acquisition III Life Sciences would command a market cap of $224 million. 

The company is led by Chairman John Frank, Vice Chairman of Oaktree Capital, and CEO Zaid Pardesi, Managing Director of Oaktree's private debt strategy. The executives led previous Oaktree-founded SPACs, including Oaktree Acquisition, which completed a business combination with Hims & Hers Health (Nasdaq: HIMS) in 2021, Oaktree Acquisition II, which completed a business combination with Alvotech (Nasdaq: ALVO) in 2022, and Oaktree Acquisition III, which withdrew its $325 million acquisition in 2023. The company plans to target healthcare or healthcare-related industries.

The Los Angeles, CA-based company was founded in 2024 and plans to list on the Nasdaq under the symbol OACCU. Jefferies, Citi, and UBS Investment Bank are the joint bookrunners on the deal.

In a First, Academic Center Offers Chiropractic Program

 The University of Pittsburgh is launching a Doctor of Chiropractic

opens in a new tab or window program -- the first at a major academic research center -- raising some eyebrowsopens in a new tab or window in mainstream medicine.

The program will be part of the university's school of health and rehabilitation sciences, which also includes its physical therapy, rehabilitation, and occupational therapy programs, among others. It is separate from the university's school of medicine.

"This is the first chiropractic program in the United States to be offered in a public research intensive university," Michael Schneider, DC, PhD, the director of the Doctor of Chiropractic program, told MedPage Today. "It's a big deal, not just nationally, but internationally."

Currently, there are 19 chiropractic schools in the U.S., according to the accrediting bodyopens in a new tab or window of the Council on Chiropractic Education, but none of these are affiliated with a major U.S. academic center.

The University of Pittsburgh program plans to enroll 40 students in the fall of 2025, and while its curriculum is still in development, it will span eight terms, Schneider said. In a public releaseopens in a new tab or window from February, Schneider said students "will follow all public health initiatives and recommendations and will receive clinical training side-by-side in an integrated setting with physicians, physical therapists, and other health care providers."

The release also noted that Schneider has been a principal or co-investigator on many NIH-funded studies and is "currently a co-investigator on four NIH-funded clinical research studies totaling about $30 million." He practiced as a chiropractor for more than 25 years, then received his PhD in rehabilitation science from the University of Pittsburgh in 2008 before moving into academic research, according to the release.

"Chiropractic is no longer seen as this alternative, kooky kind of profession. It has enough evidence now to show that [what] we do works and it's integrated health," Schneider told MedPage Today. "It's not alternative medicine anymore, and I think that's the way it was viewed here at the university, and why the program was approved."

Mainstream medicine has moved toward wider acceptance of treatments once perceived to fall more into the realm of "alternative" medicine, particularly for therapies like meditation and acupuncture.

While many physicians still don't refer to chiropractic, there have been hints of wider acceptance, including a 2017 clinical practice guidelineopens in a new tab or window from the American College of Physicians on treating low back pain that recommended nonpharmacologic treatments, including spinal manipulation (typically performed by a chiropractor), albeit supported only by low-quality evidence. Indeed, a handful of clinical trialsopens in a new tab or window published in recent years have suggestedopens in a new tab or window a small short-term advantage over usual care for certain conditions, including low back pain.

Mainstream medical facilities including Brigham and Women's Hospitalopens in a new tab or window and its Osher Center for Integrative Health in Boston, and the University of California San Diegoopens in a new tab or window appear to endorse chiropractic on their websites. And even Medicare coversopens in a new tab or window "manual manipulation of the spine by a chiropractor to correct a vertebral subluxation," though it says it "doesn't cover other services or tests a chiropractor's orders."

Nonetheless, chiropractic has a fraught history with traditional medicine, colored in part by an effort by the American Medical Associationopens in a new tab or window (AMA) to eliminate and delegitimize the profession. Chiropractors sued AMA on antitrust grounds and won their case in 1990.

That history still shapes physician perspectives today. Joel Zivot, MD, an anesthesiologist and intensivist at Emory University in Atlanta, told MedPage Today, "Chiropractic, I think, as an activity has a pretty high rate of complaint I believe," he said. "And usually, it's bruises or twists, or in the worst case scenarios, there are herniated discs or strokes."

"What people fear about [chiropractic] is that it's yanking on a very delicate part of the anatomy, seemingly with uncertain parameters," he said.

He said he'd be more likely to refer a patient to an occupational therapist, physical therapist, dietitian, or "other allied health disciplines," rather than a chiropractor.

Another motivation by the university, Zivot noted, could be an overall shift in the healthcare marketplace. "What is the failure of allopathic medicine? Because in many ways, it has failed in its fiduciary duty to the public. Many people are unsatisfied with it."

Traditional medicine may not address various patient issues, "And so when people feel like they go to the doctor, the doctor doesn't help them, they naturally want to go somewhere else," Zivot said.

However, he said, it can be hard for patients to decipher overlapping roles in medicine, the level of training that accompanies a particular honorific, the level of risk, and cost with any given practitioner.

The school's motivation could also be financial, Zivot added: "I don't know if they've actually made some kind of an analysis, a need in the local market, or because they just decided that they can make money on it."

While the University of Pittsburgh's school of medicine declined an interview with MedPage Today, it did provide a statement from the chair of its department of physical medicine and rehabilitation.

"This new program will support capacity building for clinicians rigorously trained in evidence-based treatments, which is much needed for spine and other musculoskeletal conditions," wrote Gwendolyn Sowa, MD, PhD.

Schneider acknowledged what he called a "historic rivalry" with the field of physical therapy, but characterized chiropractic as a more specialized practice.

"Most physical therapists will treat [the] back, but it's more general," he said. "And so there's really not another profession that really has focused just on non-surgical, non-pharmacological spine management, and that's where chiropractic fits in."

The American Academy of Physical Medicine & Rehabilitation, the American Academy of Family Physicians, and the American Physical Therapy Association all declined to comment for this story.

https://www.medpagetoday.com/special-reports/exclusives/112253

Prescribe Liraglutide to a 6-Year-Old Patient With Obesity if FDA Approved?

 As a pediatric obesity medicine specialist, I have witnessed first-hand the benefits of GLP-1 receptor agonists in the treatment of adolescent obesity. In particular, semaglutide (Wegovy) plus intensive health behavior lifestyle treatment has improved comorbid health risk factors, physical activity tolerance, sleep, body image, and self-confidence in many of the adolescents that I care for at a primary care-based clinic.

But for the many younger children (under 12 years old) I see, no matter how severe the obesity or significant the obesity-related risk factors -- like prediabetes, fatty liver, hypercholesterolemia, sleep apnea, or bullying and psychosocial distress -- no medication options are approved to accompany intensive health behavior lifestyle intervention.

That may all change soon.

The FDA is currently considering approval of liraglutide for the treatment of severe obesity in children ages 6-12. The review comes on the heels of a randomized trialopens in a new tab or window published in the New England Journal of Medicine (NEJM) demonstrating the safety and efficacy of liraglutide, added to lifestyle intervention, in treating severe obesity in this patient population.

Specifically, the multicenter trial of 82 kids found that over a 56-week treatment period, children treated with 3 mg of liraglutide plus behavioral intervention experienced a 5.8% decrease in BMI compared with a 1.6% increase in the behavioral intervention only group. Of those children who received liraglutide, 80% experienced gastrointestinal side effects, most of which were mild or moderate, compared to 54% in the placebo group.

Although the American Academy of Pediatrics' Clinical Practice Guidelineopens in a new tab or window says we "may offer children ages 8 through 11 years of age with obesity weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment," FDA approval is a necessary step before I will prescribe obesity medications in children younger than 12 years.

But still, FDA approval is not a game-changer for me. As I consider the risks versus benefits of liraglutide in this population, I anticipate benefits outweighing risks in only a select few situations. Here's an overview of what I see as the risks and benefits:

Benefits:

  • Modest reduction in BMI percentile during the treatment period.
  • Possible improvements in metabolic risk factors. (Although the trial did not find statistically significant improvements in blood pressure or hemoglobin A1c, there were trends toward improvement.)
  • Possible improvements in psychosocial risk factors associated with severe obesity (based on findings from studies of adolescents taking obesity medications), but this was not studied in the trial of liraglutide in kids 6-12.

Risks:

  • Unknown long-term safety and efficacy, including impact on growth and adult height.
  • Side effects, including unknown long-term side effects.
  • Weight gain once medication use stops. In this trial, children in the treatment group gained back nearly all the weight lost after 26 weeks off of the medication (at 82 weeks, the weight was -0.8% in the treatment group compared to +6.7% in placebo group). An open-label extension phase of the trial is ongoing, which will better elucidate longer-term outcomes.
  • Daily injection required.

Severe obesity is a disease that requires individualized treatment. In some cases, this may include GLP-1 medications for children ages 6-12 if they are FDA-approved, and following close consideration and discussion of risks, benefits, and unknowns with caregivers, and only alongside an intensive health behavior lifestyle intervention. For me, the risks outweigh the benefits of pharmacological treatment of severe obesity in children ages 6-12 most of the time.

However, if FDA approves liraglutide for children, having it as a treatment option is meaningful. My risk-benefit analysis may change as more medication options and longer-term studies of safety and efficacy become available. I am grateful to the researchers studying these treatments in children, ensuring that kids are not left behind in the obesity treatment revolution, but we must proceed with caution.

Natalie Muth, MD, MPH, MBA, RDN,opens in a new tab or window is a primary care pediatrician and obesity medicine specialist in the WELL Clinic at Children's Primary Care Medical Group in Carlsbad, California, and co-founder of Namio Health, a virtual intensive behavioral intervention for the treatment of pediatric obesity.

https://www.medpagetoday.com/opinion/second-opinions/112263